Get the Stockscreener App
60.74
0.38%
0.23
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $60.74, with a volume of 12.26M.
It is up +0.38% in the last 24 hours and up +9.88% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$60.51
Open:
$60.87
24h Volume:
12.26M
Relative Volume:
1.08
Market Cap:
$124.04B
Revenue:
$48.48B
Net Income/Loss:
$7.27B
P/E Ratio:
17.05
EPS:
3.5626
Net Cash Flow:
$11.91B
1W Performance:
+5.49%
1M Performance:
+9.88%
6M Performance:
+9.92%
1Y Performance:
+26.38%
1-Day Range:
$60.47
$62.29
1-Week Range:
$56.78
$62.29
52-Week Range:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
60.74 | 123.57B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,179.11 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
253.04 | 601.73B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
254.49 | 449.45B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
127.50 | 315.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.76 | 291.42B | 54.66B | 13.58B | 16.05B | 7.0171 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Bristol Myers Squibb Co (NYSE:BMY): A High Yield Dividend Stock Backed by Strong Profitability - ChartMill
Bristol Myers Squibb stock steadies as Opdivo and Eliquis underpin earnings power - ad-hoc-news.de
Bristol Myers Squibb stock trades steadily as Eliquis and Opdivo drive earnings and cash flow - ad-hoc-news.de
Bristol Myers Squibb stock trades steadily as cardiovascular and oncology portfolio supports earning - ad-hoc-news.de
Bristol Myers Squibb stock trades steady as oncology and immunology portfolio underpins earnings - ad-hoc-news.de
Is Bristol-Myers Squibb (BMY) Reasonable After Its 32% Run? - simplywall.st
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Bristol Myers Squibb stock trades steady as oncology revenue and Celgene legacy shape valuation - ad-hoc-news.de
Bristol Myers Squibb stock trades steady as Q1 2026 results highlight stronger Eliquis and Opdivo re - ad-hoc-news.de
Bristol Myers Squibb stock holds steady as oncology and immunology pipeline stays in focus for US in - Ad Hoc News
Bristol Myers Sues Generics Cos. Over Planned Cardiac Drug - Law360
Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada - Japan Wire by Kyodo News
Bristol-Myers Squibb Co Stock (BMY) Closed Up by 3.12% on Jul 15: Key Drivers Unveiled - TradingKey
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider - GlobeNewswire Inc.
Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada | Corporate - EQS News
Bristol-Myers Squibb Co (BMY) Shares Fall 4.0% -- What GF Score of 76 Tells Investors - GuruFocus
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Bristol-Myers Squibb Co Stock (BMY) Closed Down by 3.99% on Jul 14: Drivers Behind the Movement - TradingKey
Bristol Myers Squibb (BMY) Following FDA Acceptance Has An Undervalued Case - simplywall.st
Bristol-Myers Sues Aurobindo to Block Camzyos Heart Drug Copies - Bloomberg Law News
Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio? - Yahoo Finance
Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb - The Motley Fool
A Look at Bristol-Myers Squibb Co (BMY) After 3.1% Gain -- GF Va - GuruFocus
Bristol-Myers Squibb Co Stock (BMY) Closed Up by 3.07% on Jul 13: Key Drivers Unveiled - TradingKey
Bristol Myers Squibb (BMY) FDA Accepts New Drug Application for Mezigdomide - GuruFocus
Bristol Myers Squibb stock holds steady on pipeline focus and oncology portfolio updates - Ad Hoc News
Bristol Myers Squibb Moves Closer to New Multiple Myeloma Treatment - Benzinga
Bristol Myers Squibb stock holds steady as oncology and immunology pipeline stays central to the lon - Ad Hoc News
BMY: FDA Accepts New Drug Application for Mezigdomide in Multiple Myeloma Treatment - GuruFocus
FDA accepts Bristol Myers Squibb’s mezigdomide application - Investing.com
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma - Yahoo Finance
Bristol-Myers Squibb (BMY): Investor Outlook On Growth Potential And Dividend Stability - DirectorsTalk Interviews
Bristol Myers Squibb stock holds steady as oncology and immunology pipeline underpins long-term outl - Ad Hoc News
Did FTSE Russell’s Reclassification and Dividend Streak Just Shift Bristol-Myers Squibb’s (BMY) Investment Narrative? - simplywall.st
Is Bristol-Myers Squibb (BMY) Cheap As Index Changes Reshape Investor Exposure? - Yahoo Finance
BMY Stock Quote Price and Forecast - CNN
PRTA Stock Rises Nearly 11% in Six Months: What's Driving It? - TradingView
Bristol Myers Squibb Stock And 2 Dividend Defensives For Volatile Markets - simplywall.st
Bristol Myers Squibb (BMY) Expands QUILS Lung Cancer Detection Model Beyond Kentucky - Yahoo Finance
Bristol-Myers Squibb’s Q2 2026 Earnings: What to Expect - Yahoo Finance
Is Bristol Myers Squibb’s Shift Into Value-Defensive Indices Reshaping The Investment Case For BMY? - Yahoo Finance
Bristol Myers Squibb (BMY) Stock Still Looks Undervalued Despite Mixed Risks - simplywall.st
Bristol Myers Squibb (BMY) Stock Looks Cheap On Earnings But Mixed On Value - Yahoo Finance
Bristol-Myers Squibb balances patent headwinds and pipeline bets - AD HOC NEWS
Opdivo from Bristol-Myers Squibban immunotherapy workhorse in lung cancer care - AD HOC NEWS
As US lawmakers increase scrutiny of Chinese trials, industry fears ‘huge distraction and expense’ - Fierce Biotech
Bristol Myers Squibb outlines long-term strategy for innovative medicines - AD HOC NEWS
Eaton Vance Focused Value Opportunities Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Classic Value Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch
Bristol-Myers Squibb (BMY) Stock Analysis: A Steady Dividend Yield With A Strategic Edge - DirectorsTalk Interviews
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):